Quartette is a contraceptive drug owned by Teva Branded Pharm. It first received market authorization on 28 March 2013. Its active ingredients are Ethinyl Estradiol and Levonorgestrel. Quartette is available in tablet form for oral administration.
The generic version of Quartette is expected to become available after 11 March 2029. This date coincides with the expiration of the last Quartette patent, based on standard patent laws and barring any additional patents or exclusivity periods. The patent, US8415332, titled 'Methods of hormonal treatment utilizing ascending-dose extended cycle regimens', is currently held by Teva Branded Pharm.
Quartette is primarily used for the prevention of pregnancy. The drug works by utilizing its active ingredients, Ethinyl Estradiol and Levonorgestrel, which are forms of estrogen and progestin respectively. These hormones prevent ovulation and cause changes in the cervical mucus and uterine lining, making it harder for sperm to reach the uterus and harder for a fertilized egg to attach to the uterus.
Quartette is currently protected by 2 patents. The latest patent, US8415332 ('Methods of hormonal treatment utilizing ascending-dose extended cycle regimens'), will expire on 11 March 2029. This patent expiration will likely pave the way for generic Quartette to enter the market. Below are the details of the patent: